Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2020 Dec 3;41(2):769–782. doi: 10.1161/ATVBAHA.120.315081

Figure 2. XO inhibition improves hematological parameters.

Figure 2.

A) Experimental design. B-E) Complete blood counts shown as a delta change from 0 to 10 weeks of treatment. F) Flow cytometry was used to measure the delta change of reticulocyte percentage from 0 to 10 weeks of treatment. Values are mean ± SEM using an unpaired Student’s t test. WT, wild type; febux, febuxostat; RBCs, red blood cells.